Phase 3 Papulopustular Rosacea Study

Summary

The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.

Timeline

Start

2011-12

Primary completion

2013-08

Completion

2013-08

Drugs

Indications